Plus Therapeutics (NASDAQ:CNSY) Upgraded at Zacks Research

Zacks Research upgraded shares of Plus Therapeutics (NASDAQ:CNSY) from a strong sell rating to a hold rating in a research report report published on Thursday morning,Zacks reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Monday, November 2nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Plus Therapeutics Stock Up 23.3%

Shares of NASDAQ:CNSY traded up $0.18 during trading on Thursday, hitting $0.95. 8,046,110 shares of the company were exchanged, compared to its average volume of 1,810,277. The stock has a 50 day simple moving average of $1.70. The firm has a market cap of $7.21 million, a P/E ratio of -0.28 and a beta of 1.49. Plus Therapeutics has a 1-year low of $0.43 and a 1-year high of $18.89.

Plus Therapeutics (NASDAQ:CNSY) last announced its quarterly earnings results on Friday, November 13th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16). Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. The firm had revenue of $0.72 million during the quarter. On average, equities research analysts expect that Plus Therapeutics will post -4.40 EPS for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.